| Range: | 24.61-45.58 | Vol Avg: | 891653 | Last Div: | 0 | Changes: | 0.33 |
| Beta: | 0.71 | Cap: | 3.94B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jun 21 2019 | Empoloyees: | 207 | ||
| CUSIP: | 45258J102 | CIK: | 0001764013 | ISIN: | US45258J1025 | Country: | US |
| CEO: | Dr. Peter Salzmann M.B.A., M.D. | Website: | https://immunovant.com | ||||
IMVT 26.87 Stock Price Immunovant, Inc.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Stock Details
Negative -0.50
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several...
zacks.com·Fri Nov 08 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow